NCT02540655View on ClinicalTrials.gov

Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 26, 2021

Study Completion Date

February 26, 2021

Conditions
Cerebellar Ataxia
Interventions
BIOLOGICAL

Stemchymal®

Patients will receive Stemchymal® through intravenous infusion

PROCEDURE

Excipients

Patients will receive excipients through intravenous infusion

Trial Locations (1)

Unknown

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
lead

Steminent Biotherapeutics Inc.

INDUSTRY

NCT02540655 - Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia | Biotech Hunter | Biotech Hunter